COLL Earnings Collegium Pharmaceutical, Inc
Reported EPS, revenue and net income by fiscal period (SEC EDGAR) — quarterly and annual. Full financials → Chart & overview → Latest filing
Annual results
EPS
Revenue
Net income
Quarterly results
EPS
Revenue
Net income
Reported EPS history
1–47 of 47
| Q2 2026 | 2026-06-30 | -0.46 | 2026-08-06 | 10-Q |
| Q1 2026 | 2026-03-31 | 0.40 | 2026-05-07 | 10-Q |
| Q4 2025 | 2025-12-31 | 0.46 | 2026-02-26 | 10-K |
| FY 2025 | 2025-12-31 | 1.73 | 2026-02-26 | 10-K |
| Q3 2025 | 2025-09-30 | 0.84 | 2025-11-06 | 10-Q |
| Q2 2025 | 2025-06-30 | 0.34 | 2025-08-07 | 10-Q |
| Q1 2025 | 2025-03-31 | 0.07 | 2025-05-08 | 10-Q |
| Q4 2024 | 2024-12-31 | 0.36 | 2025-02-27 | 10-K |
| FY 2024 | 2024-12-31 | 1.86 | 2025-02-27 | 10-K |
| Q3 2024 | 2024-09-30 | 0.27 | 2024-11-07 | 10-Q |
| Q2 2024 | 2024-06-30 | 0.52 | 2024-08-08 | 10-Q |
| Q1 2024 | 2024-03-31 | 0.71 | 2024-05-09 | 10-Q |
| Q4 2023 | 2023-12-31 | 0.82 | 2024-02-22 | 10-K |
| FY 2023 | 2023-12-31 | 1.29 | 2024-02-22 | 10-K |
| Q3 2023 | 2023-09-30 | 0.53 | 2023-11-07 | 10-Q |
| Q2 2023 | 2023-06-30 | 0.34 | 2023-08-03 | 10-Q |
| Q1 2023 | 2023-03-31 | -0.51 | 2023-05-04 | 10-Q |
| Q4 2022 | 2022-12-31 | -0.21 | 2023-02-23 | 10-K |
| FY 2022 | 2022-12-31 | -0.74 | 2023-02-23 | 10-K |
| Q3 2022 | 2022-09-30 | 0.01 | 2022-11-03 | 10-Q |
| Q2 2022 | 2022-06-30 | -0.15 | 2022-08-04 | 10-Q |
| Q1 2022 | 2022-03-31 | -0.39 | 2022-05-10 | 10-Q |
| Q4 2021 | 2021-12-31 | -0.73 | 2022-02-24 | 10-K |
| FY 2021 | 2021-12-31 | 1.86 | 2022-02-24 | 10-K |
| Q3 2021 | 2021-09-30 | 0.22 | 2021-11-04 | 10-Q |
| Q2 2021 | 2021-06-30 | 1.79 | 2021-08-05 | 10-Q |
| Q1 2021 | 2021-03-31 | 0.41 | 2021-05-06 | 10-Q |
| Q4 2020 | 2020-12-31 | 0.20 | 2021-02-25 | 10-K |
| FY 2020 | 2020-12-31 | 0.76 | 2021-02-25 | 10-K |
| Q3 2020 | 2020-09-30 | 0.32 | 2020-11-05 | 10-Q |
| Q2 2020 | 2020-06-30 | 0.23 | 2020-08-05 | 10-Q |
| Q1 2020 | 2020-03-31 | 0.01 | 2020-05-07 | 10-Q |
| Q4 2019 (derived) | 2019-12-31 | -0.07 | — | — |
| FY 2019 | 2019-12-31 | -0.68 | — | — |
| Q3 2019 | 2019-09-30 | -0.18 | — | — |
| Q2 2019 | 2019-06-30 | -0.14 | — | — |
| Q1 2019 | 2019-03-31 | -0.29 | — | — |
| Q4 2018 | 2018-12-31 | 0.27 | 2019-02-27 | 10-K |
| FY 2018 | 2018-12-31 | -1.19 | — | — |
| Q3 2019 | 2018-09-30 | -0.50 | — | — |
| Q2 2019 | 2018-06-30 | -0.40 | — | — |
| Q1 2019 | 2018-03-31 | -0.57 | — | — |
| Q1 2016 | 2016-03-31 | -0.68 | 2016-05-11 | 10-Q |
| Q4 2015 | 2015-12-31 | -0.46 | 2016-03-18 | 10-K |
| Q3 2016 | 2015-09-30 | -0.46 | — | — |
| Q2 2016 | 2015-06-30 | -0.45 | — | — |
| Q1 2016 | 2015-03-31 | -0.65 | — | — |
Source: SEC EDGAR / XBRL (reported actuals; no consensus estimates). Some issuers (e.g. mortgage REITs, banks) don't report a conventional revenue line, so those charts may be omitted. Q4 EPS marked "derived" is computed as the fiscal-year EPS minus Q1–Q3 (10-Ks report only the annual figure); EPS is not strictly additive across quarters, so it can differ by a cent or two from the issuer's own Q4. A period with no "Reported" date is known only from a later filing's prior-year comparative. Informational only — not financial advice.